Impact of risk of generalizability biases in adult obesity interventions: A meta‐epidemiological review and meta‐analysis by Beets, Michael W. et al.
R E V I EW
Impact of risk of generalizability biases in adult obesity
interventions: A meta-epidemiological review and meta-analysis
Michael W. Beets1 | Lauren von Klinggraeff1 | Sarah Burkart1 | Alexis Jones1 |
John P. A. Ioannidis2 | R. Glenn Weaver1 | Anthony D. Okely3 | David Lubans4 |
Esther van Sluijs5 | Russell Jago6 | Gabrielle Turner-McGrievy7 |
James Thrasher7 | Xiaoming Li7
1Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA
2Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, and Meta-Research Innovation Center at Stanford
(METRICS), Stanford University, Stanford, CA, USA
3Faculty of the Arts, Social Sciences and Humanities, School of Education, University of Wollongong, Wollongong, New South Wales, Australia
4School of Education, Priority Research Centre in Physical Activity and Nutrition, University of Newcastle, Callaghan, New South Wales, Australia
5Centre for Diet and Activity Research (CEDAR), MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK
6Centre for Exercise Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK
7Department of Health Promotion, Education, and Behavior Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA
Correspondence
Michael W. Beets, Department of Exercise
Science, Arnold School of Public Health,
University of South Carolina, 921 Assembly
Street, Columbia, SC 29203, USA.
Email: beets@mailbox.sc.edu
Funding information
National Health and Medical Research Council,
Grant/Award Numbers: APP1154507,
APP1176858; National Heart, Lung, and Blood
Institute, Grant/Award Numbers:
F31HL158016, F32HL154530,
R01HL149141; National Institute of General
Medical Sciences, Grant/Award Number:
P20GM130420; Sue and Bob O'Donnell
Summary
Biases introduced in early-stage studies can lead to inflated early discoveries. The risk
of generalizability biases (RGBs) identifies key features of feasibility studies that,
when present, lead to reduced impact in a larger trial. This meta-study examined the
influence of RGBs in adult obesity interventions. Behavioral interventions with a pub-
lished feasibility study and a larger scale trial of the same intervention (e.g., pairs)
were identified. Each pair was coded for the presence of RGBs. Quantitative out-
comes were extracted. Multilevel meta-regression models were used to examine the
impact of RGBs on the difference in the effect size (ES, standardized mean difference)
from pilot to larger scale trial. A total of 114 pairs, representing 230 studies, were
identified. Overall, 75% of the pairs had at least one RGB present. The four most
prevalent RGBs were duration (33%), delivery agent (30%), implementation support
(23%), and target audience (22%) bias. The largest reductions in the ES were observed
in pairs where an RGB was present in the pilot and removed in the larger scale trial
(average reduction ES 0.41, range 1.06 to 0.01), compared with pairs without an
RGB (average reduction ES 0.15, range 0.18 to 0.14). Eliminating RGBs during
early-stage testing may result in improved evidence.
K E YWORD S
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Abbreviations: CMA, comprehensive meta-analysis; ES, effect size; MeSH, Medical Subject Headings; RGB, risk of generalizability bias.
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1 | INTRODUCTION
In the United States alone, investing in clinical trials is a multibillion-
dollar enterprise. For behavioral interventions, it is common to per-
form one or more early-stage studies before launching larger scale
trials.1,2 These early-stage studies (referred to herein as pilot/
feasibility studies) lay the foundation for more definitive hypothesis
testing in larger scale clinical trials by providing preliminary evi-
dence on the effects of an intervention and evidence for the feasi-
bility of trial (e.g., recruitment) and intervention (e.g., fidelity)
related facets.3 Pilot/feasibility studies are consistently depicted as
playing key roles in translational science frameworks for developing
behavioral interventions by providing evidence about whether an
intervention can be done and demonstrates initial promise.1,2,4,5
Well-designed and executed pilot/feasibility studies, thus, serve as
the cornerstone for decisions regarding the execution of larger
scale clinical trials, and funding for larger scale trials often requires
these pilot studies (e.g., R01 grants from US National Institutes of
Health [NIH]).
A challenge many researchers face in the design and execution of
a pilot/feasibility study is the ability to translate initially promising
findings of an intervention into an intervention that demonstrates
efficaciousness when evaluated in a larger scale trial. The transition
from early-stage, often small, pilot/feasibility studies to progressively
larger trials is commonly associated with a respective drop in the
impact of an intervention that can render an intervention tested in
the larger trial completely inert.6–8 Referred to as a scaling penalty9,10
in the dissemination/implementation literature, a similar phenomenon
is observed in the sequence of studies from pilot/feasibility to pro-
gressively larger size trials.11
This initial promise followed by reduced effectiveness may be
from the introduction of biases during the early-stage of testing that
lead to exaggerated early effects. Biases, in the scientific literature on
clinical trials, are typically thought of in relation to internal validity,
which focus on issues resulting from randomization and blinding pro-
cedures, incomplete data and selective reporting of outcomes.12,13
Although important, internal validity issues do not address other con-
textual factors that may lead to overestimation or underestimation of
effects, especially in behavioral interventions. In the behavioral sci-
ence field, a newly developed set of biases have been conceptualized
that address contextual factors in behavioral interventions that, when
present, could lead to inflated effects.11 Referred to as risk of general-
izability biases (RGBs), these focus on contextual factors associated
with external validity or the degree to which features of the interven-
tion and sample in the early-stage pilot/feasibility study are not scal-
able or generalizable to the next stage of testing in a larger, more
well-powered trial. RGBs focus broadly on the conduct of behavioral
interventions by including items related to where an intervention was
delivered, by whom and to whom an intervention was delivered, and
other support necessary to deliver the intervention. The RGBs focus
on changes in these from the early-stage pilot/feasibility studies to
the larger scale trial and how such changes can potentially lead to
diminished effects in the large-scale trial. The RGBs, therefore,
represent contextual features that any number of behavioral interven-
tions, regardless of theoretical and methodological approach or
behavior targeted, encounter in the design and execution of an
intervention.
An initial study11 provided preliminary support for the impact of
RGBs in childhood obesity trials. This study showed larger scale tri-
als that were informed by pilot/feasibility trials with an RGB had
substantially greater reductions in outcomes in comparison with
larger scale trials informed by pilot/feasibility studies without an
RGB. This, however, was demonstrated in a relatively small number
of interventions (total of 39) that had a published pilot/feasibility
study and a published larger scale trial on a topic related to child-
hood obesity. Given pilot/feasibility studies provide evidence to
inform decisions about investing in larger scale trials, they should be
conducted without the introduction of biases. We believe the RGBs
represent a unique set of biases behavioral interventionist face and
have the potential to inform important aspects in the design and
execution of pilot/feasibility studies. The purpose of this study was
to build upon previous evidence of the influence of RGBs and
evaluate their impact in a sample of published pilot/feasibility
studies and larger scale trials of the same behavioral intervention on
a topic related to adult obesity.
2 | METHODS
The methods are similar to the methods used in a previous meta-
epidemiological investigation of RBGs in trials of childhood obesity.11
Specifically, comprehensive, meta-epidemiological review procedures
were used to identify behavioral interventions focused on adult obesity
(age range ≥18 years) that have a published preliminary, early-stage
testing of the intervention and a published larger scale trial of the same
intervention. Consistent with our prior work, behavioral interventions
were defined as social science/public health intervention involving a
coordinated set of activities targeted at one or more levels including
interpersonal, intrapersonal, policy, community, macro-environments,
micro-environments, and institutions1,14–16 and obesity-related topics
could include diet, exercise, physical activity, screen time, sleep,
sedentary behavior, or combination of these behaviors. “Behavioral
intervention pilot studies” were defined as studies which test the feasi-
bility of a behavioral intervention and/or provide evidence of a prelimi-
nary effect(s) in a hypothesized direction.1,17,18 These studies are
conducted separately from, and prior to, larger scale trials, with the
results used to inform the subsequent testing of the same or refined
intervention.1,18 Behavioral intervention pilot studies can also be
referred to as “feasibility,” “preliminary,” “proof-of-concept,”
“vanguard,” “novel,” or “evidentiary”.1,19,20
2.1 | Data sources and search strategy
To identify pilot/feasibility studies and larger scale trials of behavioral
interventions on a topic related to adult obesity the following
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procedures were used. First, a combination of controlled vocabulary
terms (e.g., MeSH and Emtree), free-text terms, and Boolean opera-
tors were used to identify eligible reviews and meta-analysis across
OVID Medline/PubMed; Embase/Elsevier; EBSCOhost; and Web of
Science. Searches for meta-analyses and reviews allowed for the iden-
tification of a large number of behavioral intervention studies in a
time effective manner and is a primary mechanism of study identifica-
tion in meta-epidemiological studies.21 Each search contained one or
more of the following terms for participant age—adult (i.e., 18 years
and older)—and one of the follow terms related to obesity—obesity,
weight, physical activity, diet, screen, sleep, sedentary, exercise, and
study design—systematic review or meta-analysis of behavioral inter-
ventions. A detailed record of the search strategy is provided in the
Data S1.
All identified systematic reviews and/or meta-analysis were
uploaded in an EndNote Library (v. X9.2). Each resulting title/
abstract of the systematic reviews and meta-analysis were screened
by at least two independent reviewers (LV, SB, AJ) in Covidence
(Covidence.org, Melbourne, Australia) prior to full-text review. All
articles included with the systematic reviews and/or meta-analyses
were retrieved and uploaded into an NVivo (v.12, Doncaster,
Australia) file for text-mining. Articles from the reviews were text-
mined using text search query to identify them as either (1) self-
identified preliminary testing of an intervention or (2) larger scale
trial referring to prior preliminary work. This was done using terms
such as “pilot, feasible, preliminary, protocol previously, rationale,
elsewhere described, prior work” to flag sections of text. Once
flagged, each section of text was reviewed to determine whether it
met inclusion criteria and then tagged as either a larger scale or
smaller-scale study. After being identified and tagged as a larger
scale trial, a “follow back” approach was used to identify references
to preliminary testing of an intervention within the body of the arti-
cle (Figure 1, Steps 4.1–4.2). Where larger scale trials indicated pre-
vious published pilot/feasibility testing of the intervention, the
referenced article was retrieved and reviewed to determine if it
met the definition of pilot/feasibility study. For studies self-
identified as pilot/feasibility, studies were “follow forward” using
the Web of Science Reference Search interface to identify any
subsequent published study referencing the identified pilot/
feasibility study as preliminary work (Figure 1, Steps 5.1–5.2; L. V.
and S. B.). Successfully paired pilot/feasibility studies and larger
scale trials identified in both the forward and backward approaches
were catalogued (Figure 1, Steps 4.3 and 5.3), and narrative and
analytic information was extracted (A. J., S. B., and L. V.) prior to
meta-analytic modeling.
2.2 | Inclusion criteria
To be included, studies were required to study adults 18 years of age
or older participating in a behavioral intervention on a topic related to
obesity. Pairs of studies were included if they had published pilot/
feasibility study and a larger scale trial of the same or similar interven-
tion and were published in English.
2.3 | Exclusion criteria
Pairs were excluded if either the pilot study reported only outcomes
associated with compliance to an intervention (e.g., feasibility met-
rics, attendance, and adherence, N = 13) and no measures on pri-
mary or secondary outcomes, or the published pilot study or larger
scale trial provided point estimates for the outcomes but did not
provide a measure of variance (e.g., SD, SE, 95% CI, N = 15).
2.4 | Data management procedures
2.4.1 | Coding RGBs
The RGBs were coded in each pilot and larger scale trial pair according
to previously established criteria11 and are defined in Table 1. Within
each pair of pilot/feasibility study and larger scale trial, two reviewers
independently reviewed the entire article to identify the presence or
absence of one or more RGBs. For the purpose of this review, eight of
the nine originally defined RGBs were extracted for analyses, with the
F IGURE 1 Diagram of search procedures of locating pilot studies and larger scale trial pairs
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RGB outcome bias not coded because no analytical comparison for
outcomes between a pilot and larger scale trial could be made on this
RGB. RGBs were established by comparing the description provided
in the pilot/feasibility study regarding the intensity of the
intervention, the amount of support to implement, who delivered the
intervention, to whom the intervention was delivered, the duration of
the intervention, the locale of where the intervention was delivered,
the types of measurements used to collect outcomes, and the
direction of the findings. For example, a pilot/feasibility study may
indicate all intervention sessions were led by the first author, whereas
in the larger scale trial, the intervention was delivered by community
health workers. In this instance, the pair would be coded as having the
risk of delivery agent bias present in the pilot/feasibility study and not
in the larger scale trial. Where discrepancies were encountered or
clarifications were required, a third reviewer was brought in to assist
in the final coding.
TABLE 1 Operational definition of risk of generalizability biases
Risk of generalizability bias Example of bias
What is the potential for difference(s)
between …
Intervention intensity bias … the number and length of contacts in the
pilot study compared with the number
and length of contacts in the larger scale
trial of the intervention?
7 sessions in 7 weeks in pilot/feasibility
study vs. 4 sessions over 12 weeks in
larger scale trial. 24 contacts per week for
12 weeks in pilot/feasibility vs. 2
contacts per week for 12 weeks in larger
scale trial
Implementation support bias … the amount of support provided to
implement the intervention in the pilot
study compared with the amount of
support provided in the larger scale trial?
Any adherence issues noted were
immediately addressed in ongoing
supervision.
At the end of each session, the researcher
debriefed with the interventionist to
discuss reasons for the variation in
approach and to maintain standardization,
integrity of implementation, and reliability
among interventionists.
Intervention delivery agent bias … the level of expertise of the individual(s)
who delivered the intervention in the
pilot study compared with who delivered
the intervention in the larger scale trial
All intervention sessions were led by the
first author.
The interventionists were highly trained
doctoral students or a postdoc.
Target audience bias … the demographics of those who received
the intervention in the pilot study
compared with those who received the
intervention in the larger scale trial
Affluent and educated background, mostly
White non-Hispanic.
Participants were predominately healthy
and well-educated.
Intervention duration bias … the length of the intervention provided in
the pilot study compared with the length
of the intervention in larger scale trial?
8-week intervention in pilot/feasibility
study to 12-month intervention in larger
scale trial.
Setting bias … the type of setting where the
intervention was delivered in the pilot
study compared with the setting in the
larger scale trial
A convenience sample of physicians, in one
primary care office practice agreed to
participate. They were approached
because of a personal relationship with
one of the investigators who also was
responsible for providing physician
training in the counseling intervention.
The study was conducted at a university
health science center.
Measurement bias … the measures employed in the pilot study
compared with the measures used in the
larger scale trial of the intervention for
primary/secondary outcomes?
Use of objective measures in pilot to self-
report measures in larger scale trial.
Directional conclusions Are the intervention effect(s) in the
hypothesized direction for the pilot study
compared with those in the larger scale
trial?
Outcomes in the opposite direction (e.g.,
control group improved more so than
treatment group).
Note: Based on definitions originally appearing in Beets et al.11
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2.4.2 | Meta-analytical procedures
Standardized difference of means (SDM) effect sizes were calculated
for each study across all reported outcomes. The steps outlined by
Morris and DeShon22 were used to create effect size estimates
from studies using different designs across different interventions
(independent groups pretest/posttest; repeated measures single
group pretest/posttest) into a common metric. For each study,
individual effect sizes and corresponding 95% confidence intervals
(CI) were calculated for all outcome measures reported in the
studies.
To ensure comparisons between pilot and larger scale pairs were
based upon similar outcomes, we classified the outcomes reported
across pairs (i.e., pilot and larger scale trial) into seven categories that
represented all the data reported.23 These were measures of body
composition (e.g., body mass index [BMI], percent body fat, skinfolds),
physical activity (e.g., moderate-to-vigorous physical activity),
sedentary behaviors (e.g., TV viewing and sitting), psychosocial
(e.g., self-efficacy and social support), diet (e.g., kcals and fruit/
vegetable intake), physiological (e.g., high-density lipoprotein [HLD],
low-density lipoprotein [LDL], and glucose), or sleep (e.g., duration,
onset, and offset). Only outcomes within common categories repre-
sented across both the pilot and the larger scale trial were included in
analyses. For instance, a study could have reported data related to
body composition, physiological, and physical activity in both the pilot
and larger scale trial, but also reported sedentary outcomes for the
pilot only and psychosocial related outcomes for the larger scale only.
In this scenario, only the body composition, physiological, and physical
activity variables would be compared across the two studies within
the pair. For studies that reported multiple outcomes within a given
category, all outcomes were extracted, and the shared correlations
among outcomes from the same trial were accounted for in the ana-
lytical models (see below for details).
All individual outcome measures reported within categories
across pairs were extracted and entered into an Excel file. Once a pair
was completely extracted and reported data transformed
(e.g., standard errors transformed into standard deviations), data were
transferred into Comprehensive Meta-Analysis (CMA) software
(v3.3.07) to calculate a SDM for effects reported in a study. After all
outcomes across all pairs were entered into CMA, the complete data
file was exported as a comma separated file and uploaded into the R
environment24 for final data analyses to occur.
Consistent with our previous study11 all effect sizes were
corrected for differences in the direction of the scales so that positive
effect sizes corresponded to improvements in the intervention group,
independent of the original scale's direction. This correction was per-
formed for simplicity of interpretive purposes so that all effect sizes
were presented in the same direction and summarized within and
across studies.
The primary testing of the impact of the biases was performed
by comparing the change in the SDM from the pilot study to the
larger scale trial for studies coded with and without a given bias pre-
sent. All studies reported more than one outcome effect; therefore,
summary effect sizes were calculated using a random-effects multi-
level robust variance estimation meta-regression model,25–27 with
outcomes nested within studies nested within pairs in the R environ-
ment24 using the package metafor.27 This modeling procedure is dis-
tribution free and can handle the non-independence of the effects
sizes from multiple outcomes reported within each of the seven cat-
egories reported within a single study. The difference in the SDM
from the pilot and larger scale trial were quantified according to pre-
viously defined formulas for the scale-up penalty,9,10 which is calcu-
lated as follows: the SDM of the larger scale trial was divided by the
SDM of the pilot and then multiplied by 100. A value of 100% indi-
cates identical SDMs in both the pilot and larger scale trial. A value
of 50% indicates that the larger scale trial was half as effective as
the pilot study; a value above 100% indicates the larger scale trial is
more effective than the pilot, whereas a negative value indicating
that the direction of the effect in the larger scale trial is opposite
that of the pilot.
A secondary evaluation of the impact of the biases was per-
formed by examining the presence/absence of the biases on the
occurrence of a nominally statistically significant (i.e., p ≤ 0.05) out-
come in the larger scale trials. These analyses were restricted to the
p values for the individual outcomes in the larger scale trials, only.
p values for each individual effect size were estimated within the
Comprehensive Meta-Analysis software based upon the effect size
and its associated standard error. p values from publications were not
used because they were either not reported or reported as truncated
values (e.g., p < 0.01). p values were dichotomized as p > 0.05 and
p ≤ 0.05 based on conventional behavioral intervention studies. Logis-
tic regression models, using robust variance estimators, were used to
examine the odds of a nominally statistically significant outcome in
the larger scale trial based on the presence/absence of the biases.
Across all models, we controlled for the influence of all other biases.
Because it has been recently proposed that statistical significance
thresholds should become p < 0.005 rather than p < 0.05,28,29 we also
explored these analyses using the p < 0.005 threshold.28,29
3 | RESULTS
A PRISMA diagram for the literature search is presented in Figure 2.
From the 114 pairs, a total of 1160 effects were extracted from
the pilot studies (average 20 [SD ± 14] effects per study) and 1089
effects extracted from the larger scale trials (average 16 [SD ± 9]
effects per trial). Studies were published between 1993 through
2020. Overall, the most commonly reported outcomes were body
composition (54% of studies), physiological (51%), physical activity
(50%), and psychosocial (29%), and diet (22%). The median sample size
of the pilot studies was 44 (range 8 to 770, average 74) while the
median sample size of the larger scale trials was 201 (range 45 to
5801, average 361). A total of 71% of the pilot studies utilized a ran-
domized design while 92% of the larger scale trials utilized this design
with the remaining 8% using either a single group pre/post design or
two group non-randomized design.
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The prevalence of the RGBs across the 114 pairs is reported in
Figure 3. Overall, 25% of the pairs were coded as no presence of any
biases, 30% containing 1 bias, 33% containing 2 biases, and 12% with
3 or 4 biases. The four most prevalent RGBs were duration (33%),
delivery agent (30%), implementation support (23%), and target audi-
ence (22%) bias.
The impact of the RGBs on trial-related outcomes are presented
in Figure 4. For pairs where the pilot was coded as having an RGB pre-
sent and in the larger scale trial, the RGB was no longer present, the
SDM decreased by an average of ΔSDM 0.41, range 1.06 to 0.01.
The largest reductions in the SDM were observed for implementation
support (pairs = 5, ΔSDM 1.06, 95% CI [2.26, 0.132]) and setting
(pairs = 4, ΔSDM 1.01, 95% CI [1.56, 0.46]), followed by target
audience (pairs = 13, ΔSDM 0.42, 95% CI [0.62, 0.22]), interven-
tion intensity (pairs = 3, ΔSDM 0.28, 95% CI [0.59, 0.04]), and
delivery agent (pairs = 15, ΔSDM 0.25, 95% CI [0.43, 0.06])
biases in comparison with pairs where these biases were not coded as
present in the pilot or larger scale trial.
Four of the RGBs were coded as present in the pilot and
larger scale trial: delivery agent (pairs = 19), implementation
support (pairs = 21), target audience (pairs = 12), and setting
(pairs = 7). Three of these four biases were associated with a
smaller reduction in the SDM in comparison with pairs without the
biases present. Implementation support and setting biases were
associated with a reduction of 0.09 (0.23 to 0.04) and 0.10
(0.37 to 0.17), respectively, whereas target audience bias was
associated with an increased effect in the larger scale trial (+0.10,
0.05 to 0.25). The presence of intervention duration, directional
conclusions, and measurement biases were not associated with a
larger reduction in the SDM compared with pairs without these
biases present.
The scale-up penalties associated with the RGBs are presented in
Figure 4. Overall, on average, pairs with biases present in the pilot and
removed in the larger scale trial's effects were 33% (range 10% to
104%) of those reported in the pilot/feasibility study. This is
compared with 63% (range 55% to 65%) for pairs without biases in
either the pilot or larger scale trial. Further, for pairs where a bias was
present in both the pilot and the larger scale trial, the larger scale trial
effect was 86% (range 60% to 136%) of the effect observed in the
pilot/feasibility study.
F IGURE 2 PRISMA diagram of
systematic literature search and final studies
included in analyses
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The impact of the RGBs on the probability of a statistically
significant outcome are presented in Table 2, and the distribution
of the z value is presented in Figure 5. Pairs coded as having either
delivery agent, setting, intervention intensity, or directional conclu-
sions biases in the pilot study and not in the larger scale trial
exhibited a reduced odds of detecting a nominally statistically sig-
nificant effect of p < 0.05 in the larger scale trials compared with
pairs without an RGB present. Two (target audience and setting
biases) of the four RGBs were coded as present in the pilot and
larger scale trial; these larger scale trials were more likely to report
a nominally statistically significant effect of p < 0.05 in comparison
with pairs without the RGB present. For detecting a statistical
effect at p < 0.005, pairs coded as having either delivery agent, set-
ting, duration, or intensity bias in the pilot study and not in the
larger scale trial exhibited a reduced odds of detecting a nominally
statistically significant effect of p < 0.005 in the larger scale trials
compared with pairs without an RGB present. Consistent with the
analyses for p < 0.05, two (target audience and setting biases) of
the four RGBs that were coded as present in the pilot and larger
scale trial, these larger scale trials were more likely to report a sta-
tistically significant effect of p < 0.005 in comparison with pairs
without the RGB present.
4 | DISCUSSION
Informative, early-stage pilot/feasibility studies may provide valuable
information about whether an intervention is ready to be tested in a
larger scale trial. When early-stage studies include features that result
in incorrect conclusions about an intervention's viability, this can lead
to premature scale-up and, ultimately, intervention failure when eval-
uated at scale. The purpose of this meta-epidemiological review was
to examine the influence of a set of recently catalogued biases—the
RGBs—that, when present in pilot/feasibility studies, can lead to
reduced effectiveness in larger scale trials. As in a prior study focused
on childhood obesity interventions,11 the presence of an RGB in a
pilot/feasibility study tended to be associated with reduced effects in
the larger scale intervention and a reduced probability of detecting a
nominally statistically significant effect. Further, the prevalence of the
RGBs across the 114 pairs of published pilots and larger scale trials of
the same intervention was high, with three out of four pairs con-
taining at least one RGB. The most impactful RGBs were delivery
agent, implementation support, target audience, setting, and interven-
tion intensity bias, although data were limited for each RGB to allow a
reliable ranking of the magnitude of these biases. These findings on
the prevalence and impact of RGBs on the effectiveness of larger
F IGURE 3 Classification of the presence (red circle) and absence (green circle) risk of generalizability biases across pilot and larger scale trial
pairs
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scale trials have implications for the behavioral intervention field
because early-stage studies with RGBs appear to produce misleading
results about the readiness of an intervention for scaling.
When moving from smaller, early-stage studies to trials to
progressively larger sample sizes, it is not uncommon nor unexpected
to see a drop in the respective impact (i.e., voltage) of an
intervention.8–10 Our findings of reduced effects in the larger scale tri-
als compared with the effects from the pilot/feasibility studies match
this pattern. This pattern, however, becomes accentuated when RGBs
are considered. Pairs where an RGB was present in the pilot/
feasibility study (i.e., delivery agent, implementation support, target
audience, setting, and intervention intensity) and not present in the
larger scale trial resulted in a greater scaling penalty, compared with
pairs where an RGB was not present. Conversely, two of the four
RGBs (setting and target audience) that could be carried forward
(i.e., present in both the pilot/feasibility and larger scale trial) showed
less of a scaling penalty or demonstrated a greater effect in the larger
scale trial. These findings, both quantitatively and conceptually, fit the
patterns expected with the presence of an RGB and provide evidence
of their impact on the outcomes reported in larger scale trials.
Comparing effect sizes generated from pilot/feasibility studies to
their larger scale trial is not without limitations, given the lower
precision attributed with effect size estimations from pilot/feasibility
studies.17,30–32 Thus, we recognize that effect sizes in pilot studies are
estimated with large uncertainty; therefore, putting too much trust on
point estimates may be misleading. To address this, we conducted
analyses considering only the larger scale trial outcomes and the prob-
ability of detecting nominally statistically significant effects (p < 0.05
and p < 0.005). This approach eliminated the issues associated with
using effects from the pilot/feasibility studies, instead relying solely
upon those effects presented in the larger scale trial. Again, findings
demonstrated the presence of RGBs have an impact on the statistical
significance in larger scale trials. When larger scale trials without an
RGB are informed by a pilot/feasibility study with an RGB, the large-
scale study had a lower probability of detecting a nominally statisti-
cally significant effect compared with larger scale trials without an
F IGURE 4 Forest plot of the change in the standardized difference in means (SDM) of the presence, absence, or carry forward of risk of
generalizability biases from a pilot/feasibility study to a larger scale trial. No pairs contained directional conclusion bias in both the pilot and larger
scale trial. Intervention duration, intervention intensity, and measurement describe differences between smaller and larger scale studies, so they
cannot be present in both studies
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RGB in either the pilot/feasibility study or larger scale trial. An exam-
ple of this is delivering an intervention in a university setting
during the pilot/feasibility study versus delivering the intervention in
a community-based setting in the larger scale trial (setting bias). A
potential reduction in the odds of detecting a nominally statistically
significant effect is observed across most of these comparisons and
provides further support for the impact of RGBs on larger scale trial
outcomes, above and beyond any concern about comparing effect
sizes between pilot/feasibility studies and larger scale trials.
We recognize that the list of RGBs evaluated herein may not fully
capture the entirety of mechanisms that lead to successful or unsuc-
cessful larger scale trials. Recent studies4,5,33–35 describe a number of
mechanisms linked to either the successful scale-up of behavioral
interventions or that should be considered in the conduct of early-
stage implementation studies of behavioral interventions. These
include mechanisms associated with the intervention (e.g., credibility,
relevance, compatibility), organization (e.g., perceived need for inter-
vention), environment (e.g., policy context and bureaucracy), resource
team (e.g., effective leadership), scale up strategy (e.g., advocacy
strategies), and planning/management (e.g., strategic monitoring).
These are clearly critical mechanisms associated with developing a
behavioral intervention that survives the scaling process. The current
list of RGBs can have important implications and potential interactions
with studies evaluating these scaling mechanisms. For instance, the
risk of setting bias, target audience bias, delivery agent bias, and inter-
vention duration bias have the potential to influence assessments
related to whether an environment can support the intervention, an
interventions' adoption, adherence and dose received, and evaluations
of whether the intervention is compatible and relevant. Although the
list of RGBs, at this time, is likely incomplete, we believe the current
list identifies features of a study that transcend the content of the
intervention and focus on features of how it is conducted that can
lead to a lower likelihood of success in a larger scale trial.
The introduction of one or more RGBs in pilot studies could be
due to a lack of reporting and/or procedural guidelines for pilot stud-
ies that focus on topics related to RGBs. Recently, an extension to the
CONSORT statement was developed for pilot/feasibility studies.36
This statement focuses predominately on features of the research
design and conduct associated with internal validity and does not pro-
vide guidance for factors affiliated with external validity, such as the
RGBs examined herein. Other reporting guidelines, for instance
PRESCI-237,38 and TiDieR,14 incorporate elements of the RGBs and
recommend they be detailed in scientific publications (e.g., clear
description of who delivered the intervention) but do not provide a
TABLE 2 Odds for detecting a nominally statistically significant p value (p < 0.05 and p < 0.005) in a larger scale trial from the presence of a
risk of generalizability bias
Risk of generalizability bias
Odds ratio for p < 0.05 in larger scale trial Odds ratio for p < 0.005 in larger scale trial
OR (95% CI) % Effects OR (95% CI) % Effects
Delivery agent Not present Reference 34% Reference 23%
Pilot only 0.62 (0.43, 0.90) 24% 0.60 (0.39, 0.93) 15%
Both 1.39 (0.97, 2.00) 42% 0.96 (0.63, 1.47) 22%
Implementation support Not present Reference 34% Reference 22%
Pilot only 0.81 (0.42, 1.56) 30% 0.54 (0.22, 1.30) 13%
Both 0.74 (0.51, 1.08) 30% 1.03 (0.67, 1.57) 22%
Target audience Not present Reference 32% Reference 20%
Pilot only 0.72 (0.47, 1.11) 26% 1.11 (0.70, 1.75) 21%
Both 2.05 (1.35, 3.12) 49% 2.51 (1.58, 3.98) 34%
Setting Not present Reference 33% Reference 21%
Pilot only 0.17 (0.06, 0.47) 8% 0.22 (0.07, 0.70) 6%
Both 2.01 (1.29, 3.14) 48% 2.49 (1.54, 4.03) 35%
Intervention duration Not present Reference 34% Reference 23%
Pilot only 0.83 (0.61, 1.12) 32% 0.60 (0.42, 0.84) 17%
Intervention intensity Not present Reference 34% Reference 22%
Pilot only 0.06 (0.01, 0.46) 3% 0.12 (0.02, 0.90) 3%
Measurement Not present Reference 35% Reference 22%
Pilot only 0.86 (0.52, 1.41) 15% 0.93 (0.52, 1.65) 20%
Directional conclusions Not present Reference 34% Reference 23%
Pilot only 0.27 (0.13, 0.52) 32% 0.25 (0.10, 0.60) 8%
Note: Bolded values 95% confidence intervals (CIs) do not cross 1.00. Reference group is pilot/feasibility study and larger scale trial pairs without a risk of
generalizability bias present.
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rationale for why interventionists may want to consider not introduc-
ing an RGB into their early-stage study. A lack of guidelines may stem
from the limited evidence, to date, demonstrating the potential impact
of the RGBs on early-stage studies and their larger scale trial out-
comes. Thus, the scientific field may be relatively unaware of the
potential influence that the inclusion of RGBs in preliminary studies
has on decisions related to scaling behavioral interventions.
Another potential reason for introducing RGBs is the need to
demonstrate early success in a pilot study to receive funding for a
larger scale trial. Large-scale trials require strong preliminary data.
Embedding RGBs into early-stage studies may provide a means to this
end. A researcher may unwittingly or unintentionally introduce RGBs
within preliminary studies to enhance perceived scientific credibility
of the evidence to support a larger scale trial. Given the hyper-
competitive funding environment, producing strong preliminary data,
which includes clearly demonstrating preliminary efficacy and promise
of an intervention, may provide a logical rationale for testing an inter-
vention at the early stages with one or more RGBs embedded within.
Despite how justified and RGB introduction may be, our findings indi-
cate that doing so has important ramifications for the outcomes of
larger scale trials. With larger scale trials of interventions requiring
some form of preliminary data, combined with the widespread
introduction of RGBs within early pilot work, an environment is
potentially created where awarding grants to support large-scale stud-
ies is high risk, because the pilot/feasibility work no longer provides
reliable evidence of an intervention's likelihood of success.
Every occurrence of an RGB, however, is not inappropriate. On
the contrary, RGBs within “first run” interventions can prove useful
for refining intervention components. Investigators who deliver
interventions themselves might gain insight about how participants
react to content and whether changes are necessary. Employing
RGBs may be necessary during the very early-stages of testing, but
only if such studies lead to another pilot without RGBs present. The
problem arises when “first run” interventions with RGBs go directly
to a larger scale trial, without conducting an intermediary trial that
more closely mimics the conditions of the anticipated larger scale
trial. A sequence of studies that goes from a first run intervention to
another, progressively larger, pilot/feasibility trial then onto a larger
scale more well-powered trial, may be ideal.1,2 Conducting multiple
iterations of an intervention's content, refining the content and then
re-piloting could assist in identifying the correct ingredients for an
intervention. This sequence implies funding is available to support a
sequential, iterative process of intervention development, refine-
ment, and testing.
The following are recommendations regarding the RGBs and
early-stage preliminary studies. First, we suggest interventionists
avoid introducing RGBs. Where RGBs are introduced this needs to
be supported with rationale, such as first run interventions, and dis-
cussion whether their presence impacts outcomes. Existing guide-
lines (e.g., CONSORT) should include the RGBs in the required
reporting of pilot/feasibility studies and their subsequent larger scale
trial. In published pilot/feasibility studies, details should be provided
as to the anticipated conditions under which a larger scale trial may
be conducted and what changes, if any, to RGB-related items
(e.g., who delivers the intervention, the length of the intervention,
the setting where the intervention is conducted) may occur and how
these may influence the larger trial results. Finally, clear linkages
should be made among studies used to inform a larger scale trial.
Pilot/feasibility studies need to be clearly identified and published
and these should be clearly referred to in a subsequent larger scale
trial they informed.
There are several limitations in this study. First, while this study
represents the largest pairing of pilot and large-scale trials to date,
there are, undoubtedly, more pairs, which exist but were not captured
due to our stringent inclusion criteria. We predicated our search
F IGURE 5 Z value distribution of outcomes in larger scale trials
by the absence (green line) of risk of generalizability bias (RGB), RGB
present in pilot and absent in larger scale trial (red distribution), and
RGB present in both pilot and larger scale trial (blue distribution).
Positive z values indicate that the intervention was better than the
control group, and negative z values indicate that the control group
was better than the intervention group. Solid vertical lines represent
z ± 1.96 (p = 0.05); dashed vertical lines represent z ± 2.58
(p = 0.005)
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strategy on the premise that larger scale trials would reference publi-
shed pilot studies if they existed. Thus, our search strategies likely
resulted in a comprehensive list of pairings that could be made, albeit
small in overall number compared with the number of larger scale trials
that exist. There are instances where a larger scale trial was identified
that did not explicitly reference prior pilot/feasibility studies, and there
were instances where a pilot/feasibility study was identified but no
larger scale trial could be found. Second, the coding of the RGBs relied
upon authors to clearly provide information upon which to judge their
presence/absence. A recent study found only 12 of 200 randomized
controlled trials (RCT) provided sufficient information about who deliv-
ered the intervention.39 Other aspects of intervention reporting, such as
the location of where the intervention occurred, are also poorly detailed
in published RCTs. The ambiguousness or absence of this information
makes identification of the RGBs difficult. The analyses conducted
herein likely contain some studies that have an RGB but were coded as
not having due to inadequate reporting of these important features.
Hence, the impact of the RGBs could be greater or lesser, depending on
the outcomes of studies that have unclear reporting. Third, not all of the
RGBs demonstrated an impact. This is not entirely unexpected and
could be due to the issues raised above or the reliance upon only
114 pairs. Uncertainty about the exact magnitude of the effects of
RGBs is substantial. Finally, comparisons using pilot/feasibility effect
sizes comes with issues of inaccurate and inflated effect sizes often
observed in early-stage work. Exact replication of an effect from a
pilot/feasibility study to a larger scale trial is not the purpose of pilot/
feasibility testing. Thus, analyses comparing reported effect sizes in
pilot/feasibility study to those observed in the larger scale trial are
inherently limited. We agree effect sizes in pilot/feasibility studies can
be imprecise and inflated and that they should not be used to inform
power analyses of a larger scale trial. Yet, it is common practice for
meta-analyses to include pilot/feasibility studies in thereby giving sci-
entific credibility to the effects they report. To address this, the ana-
lyses conducted herein include both a comparison the pilot/feasibility
to larger scale effect sizes as well as solely focusing on the effects
reported in the larger scale trials. These findings were consistent
across these analyses demonstrating the impact RGBs have in trial
outcomes. Fourth, even larger scale trials may be biased or inaccurate
for many other reasons not captured by RBGs; therefore, their treat-
ment effects should not be seen as an absolute gold standard.
In conclusion, the RGBs demonstrated moderate to strong sup-
port of their influence on the success of larger scale trials. Consider-
ation of the RGBs and how they can potentially misinform decisions
about whether an intervention is ready for scale is critical given the
time and resources required to conduct larger scale trials. Future pre-
liminary, early-stage work needs to consider whether the introduction
of one or more RGBs is justifiable and if their presence will lead to
incorrect decisions regarding the viability of an intervention.
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